Back to today’s briefing

Story perspectives

FDA Grants Fast Track for Promising cLDD Therapy

2/24/2025

29 6

Summary

Story summary

BioRestorative Therapies has exciting news: the FDA has granted Fast Track designation for BRTX-100, a groundbreaking cell-based therapy aimed at chronic lumbar disc disease (cLDD). Early Phase 2 trial results are promising, with 70% of participants experiencing significant pain relief and improved function by week 26. The journey continues, with trial completion anticipated by August 2025.

1 of 1

Story summary

BioRestorative Therapies has exciting news: the FDA has granted Fast Track designation for BRTX-100, a groundbreaking cell-based therapy aimed at chronic lumbar disc disease (cLDD). Early Phase 2 trial results are promising, with 70% of participants experiencing significant pain relief and improved function by week 26. The journey continues, with trial completion anticipated by August 2025.